Antimicrobial Activities of LCB01-0183, a New Oxazolidinone |
Lee, Hyun-Hee
(School of Life Science, Handong Global University)
Jung, Sung-Ji (School of Life Science, Handong Global University) Jeong, Ji-Woong (School of Life Science, Handong Global University) Cho, Young-Lag (LegoChem BioScience, Inc.) Kim, Yong-Zu (LegoChem BioScience, Inc.) Kwak, Jin-Hwan (School of Life Science, Handong Global University) |
1 | Lobritz, M., Hutton-Thomas, R., Marshall, S. and Rice, L. B. : Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob. Agents. Chemother. 47, 3318 (2003). DOI |
2 | Mendes, R. E., Deshpande, L. M., Castanheira, M., DiPersio, J., Saubolle, M. A. and Jones, R. N. : First report of cfrmediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents. Chemother. 52, 2244 (2008). DOI ScienceOn |
3 | Diekema, D. J. and Jones, R. N. : Oxazolidinone antibiotics. Lancet 358, 1975 (2001). DOI ScienceOn |
4 | Michael, A. F. and Christopher, T. W. : Antibiotics for emerging pathogens. Science 325, 1089 (2009). DOI ScienceOn |
5 | Sreenivas, K., Amarnath, P. V. S., Mallik, A., Sarnaik, H., Selva Kumar, N., Takhi, M., Trehan, S., Sitaram Kumar, M., Iqbal, J., Rajagopalan, R. and Chakrabarti, R. : In vitro and in vivo antibacterial evaluation of DRF 8417, a new oxazolidinone. J. Antimicrob. Chemother. 60, 159 (2007). DOI ScienceOn |
6 | Levy, S. B. and Marshall, B. : Antibacterial resistance worldwide: causes, challenges and responses. Nature. Med. 10, s122 (2004). DOI ScienceOn |
7 | Noskin, G. A., Siddiqui, F., Stosor, V., Hacek, D. and Peterson, L. R. : In vitro activities of linezolid against important Grampositive bacterial pathogens including vancomycin-resistant Enterococci. Antibicrob. Agents. Chemother. 43, 2059 (1999). |
8 | Vara Prasad, J. V. : New oxazolidinones. Curr. Opin. Microbiol. 10, 454 (2007). DOI ScienceOn |
9 | Swaney, S. M., Aoki, H., Ganoza, M. C. and Shinabarger, D. L. : The oxazolidinone linezollid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents. Chemother. 42, 3251 (1998). |
10 | Gill, C. J., Abruzzo, G. K., Flattery, A. M., Misura, A. S., Bartizal, K. and Hickey, E. J. : In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrob. Agents. Chemother. 51, 3434 (2007). DOI ScienceOn |
11 | Lin, A. H., Murray, R. W., Vidamar, T. J. and Marotti, K. R. : The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents. Chemother. 41, 2127 (1997). |
12 | Jones, R. N., Ross, J. E., Castanheira, M. and Mendes, R. E. : United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62, 416 (2008). DOI ScienceOn |
13 | Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D. and Zurenko, G. : In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents. Chemother. 52, 4442 (2008). DOI ScienceOn |
14 | Leach, K. L., Swaney, S. M., Colca, J. R., McDonald, W. G., Blinn, J. R., Thomasco, L. M., Gadwood, R. C., Shinabarger, D., Xiong, L. and Mankin, A. S. : The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 26, 393 (2007). DOI ScienceOn |
15 | Moise, P. A., Forrest, A., Birmingham, M. C. and Schentag, J. J. : The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to vancomycin. J. Antimicrob. Chemother. 50, 1017 (2002). DOI ScienceOn |
16 | Meka, V. G. and Gold, H. S. : Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010 (2004). DOI ScienceOn |
17 | Clinical and Laboratory Standards Institute (CLSI) : Performance Standards for Antimicrobial Susceptibility Testing; 21th Informational Supplement. CLSI Document M100-S22. CLSI, Wayne, PA (2012). |
18 | Clinical and Laboratory Standards Institute (CLSI) : Methods for Determining Bactericidal Activity of Antimicrobial Agents. CLSI document M26-A. CLSI, Wayne, PA (1999). |
19 | Bliss, C. I. : Statistics in bioassay. Academic Press, Inc., New York (1985). |
20 | Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G. and Edwards, J. E. Jr. : Trends in antimicrobial drug development implications for the future. Clin. Infect. Dis. 38, 1279 (2004). DOI ScienceOn |
21 | Luh, K. T., Hsueh, P. R., Teng, L. J., Pan, H. J., Chen, Y. C., Lu, J. J., Wu, J. J. and Ho, S. W. : Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents. Chemother. 44, 3374 (2004). |